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Prostaglandins and cyclic nucleotides are important 
regulators of cell function and immune/int:Iammat?ry 
responses. Chediak-Higashi (CH) syndrome III man IS a 
genetic disorder characterized by pale skin, hair, and 
eye color, abnormallysosomes, and recurrent infections. 
Oculocutaneous pigment dilution and impaired leuko-
cyte function appear to be due to a defect in microtubule 
assembly. Whereas human peripheral blood polymor-
phonuclear (PMN) leukocytes do not form surface c~ps 
with concanavalin A (Con A) except after treatment WIth 
agents such: as colchicine that inhibit microtubule assem-
bly, CH PMN leukocytes exhibit spontaneous cap for-
mation. This capping is inhibited by cyclic GMP (cGMP) 
and by cholinergic agonists that increase cellular cGMP 
generation. The extensive assembly of micro tubules seen 
with the electron microscope in normal human PMN 
leukocytes incubated with Con A does not occur in PMN 
leukocytes from CH patients. Incubation of CH PMN 
leukocytes with cGMP or agents that increase cellular 
cGMP results in a marked increase in microtubule num-
bers when cells are exposed to Con A. Because ascorbic 
acid increases human leukocyte cGMP levels in vitro, CH 
patients have been treated with vitamin C. Early results 
in approximately 6 CH patients indicate that vitamin C 
therapy restores leukocyte function and prevents recur-
rent infections. 
A disease similar to human systemic lupus erythema-
tosus develops in New Zealand black and white (NZB/W) 
mice' it is characterized by impaired cell-mediated im-
munity, enhanced humoral immune responses, circulat-
ing antibodies to nuclear antigens, and immune-.comp~ex . 
glomerulonephritis. Treatment of NZB/w .D?-lCe ~th 
prostaglandin EJ prevents glomerular depOSItion of Im-
munoglobulins and complement, the development of pro-
liferative glomerulonephritis, and prolongs their sur-
vival. 
Prostaglandins and cyclic nucleotides are important regula-
tors of cell function [1,2]. Therefore, these compounds are of 
interest both to students of cutaneous pathophysiology and to 
students of cell biology. This paper presents studies on 2 seem-
ingly diverse diseases-Chediak-Higashi (CH) syndro~e and 
systemic lupus erythematosus (SLE)-that may have m com-
mon disordered prostaglandin and/or cyclic nucleotide metab-
olism and in which the skin is affected profoundly. 
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Abbreviations: 
cGMP: cyclic GMP 
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Con A: concanavalin A 
DE: dermal-epidermal 
PGE\: prostaglandin E\ 
PMN: polymorphonuclear leukocytes 
SLE: systemic lupus erythematosus 
CHEDIAK-HIGASHI SYNDROME 
In man the CH syndrome is a rare autosomal recessive 
disorder characterized by pale skin that sunburns easily, pale 
or blue-gray hair color, decreased uveal pigment, P~10to~hobia, 
frequent pyogenic infections, and the presenc.e ?f gIant, Irregu-
larly shaped lysosomes in most granule-contamH~g cells .[3]. An 
accelerated (lymphoma-like) phase occurs, dunng which pa-
tients have hepatosplenomegaly and lymphadenopathy due to 
lymphoid and histiocytic infiltrates in thes~ org~ns [4]. Death 
usually occurs in childhood as a resul.t of mfectlOn or hemor-
rhage. A similar disorder has been described in mink [5], cattle 
[6], and mice [7]. Neutropenia, presumably due to intramedul-
lary destruction of cells [8], is common and marrow granulocyte 
responses are decreased [9]. Chemotacti~ res~onses of neu~ro­
phils from man [10] and mouse [11] are ImpaIred, but pm."tJcle 
uptake by CH neutrophils is normal. The complement ot leu-
kocyte lysosomal enzymes is relatively normal [12], although 
reductions in myeloperoxidase and f3-glucuronidase have been 
reported [13]. These cells exhibit a delay in the killing. of 
intracellular bacteria [14], perhaps as a result of the selectIve 
degranulation defect that has been detected in leukocyte~ from 
CH patients [12]. A defect in intracellular translocatIOn of 
lysosomes may also explain the pigment dilution ("partial ocu-
locutaneous albinism") characteristic of the CH syndrome 
[15]: The lysosomal system appears to be important to the 
process of pigmentation. Second~ry ly~osomes (phag?lyso-
somes) are present in the lower epIdermIS, partIcularly In the 
basal cells. They digest phagocytosed melanosomes as melan-
osome complexes. The transfer of melanosomes from melano-
cytes to epidermal keratinocytes and to hair cortex cells appears 
to result from active phagocytosis of melanosomes from the 
dendritic tips of melanocytes by keratinocytes and hair cortex 
cells [16-18]. Phagocytosed melanosomes are then dispersed 
throughout the cytoplasm of the keratinocytes. In the nonex-
posed skin of Caucasians, melanin is found exclusiveJ~ .in the 
basal layer, whereas in that of Negroes moderate quantitIes m'e 
seen throughout the epidermis [19]. In Caucasians and Mon· 
goloids the melanosomes in keratinocytes lie aggregated in 
membrane-bound melanosome complexes (2 to 3 melano-
somes), and only a small portion are singly dispersed. In Ne-
groes and Australian aboriginals there m'e very few aggregates 
[19-21]' The larger size of Negro melanosomes (0.5 to 0.8 J.l vs. 
0.3 to 0.5 J.l in Caucasians) appears to account for this difference 
in the phagocytic process [22]. The membrane-bound melano-
some complexes contain acid phosphatase and therefore rep-
resent phagolysosomes in which melanosomes are being de-
graded [23). Thus, melanosomes are less dispersed and are 
probably removed more rapidly in Caucasians than in N egroes. 
Similarly, in persons with the CH syndrome, melanosomes 
remain clumped rather than dispersed throughout keratino-
cytes and hair cortex cells. The basic defect of the CH syndrome 
is not known, but it may be caused by abnormal lysosomal 
membranes. That the giant CH granules of leukocytes stain for 
acid phosphatase much more rapidly than adjacent normal 
granules suggests altered membrane structure in CH lysosomes 
[24]. Recent studies indicate that microtubule function may be 
impaired in persons with the CH syndrome. 
The abnormalities present in the beige mouse, a spontaneous 
mutant of the C57 black mouse, are considered analogous to 
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the CH syndrome of human beings [3,11,25]. Polymorphonu-
clear (PMN) leukocytes from beige (CH) mice exhibi t an ab-
normality of conca~avalin A (Con A) distribut ion that sug-
gested a defect In microtubule assembly in these cells [26]. In 
lymphocytes [27], virus-tran!1formed 3T 3 fibroblasts, and other 
cells, the disassembly of microtubules by treatment with such 
agents as colchicine and vinblastine favors the aggregation of 
Con A into a surface cap [28]; our finding that the PMN 
leukocytes from normal black mice have a random surface 
distribution of Con A except after incubation with colchicine 
(which permits cap formation) is consistent with this fact. By 
contrast, Con A was capped spontaneously on PMN leukocytes 
from the CH mice to the ame degree as colchicine-treated 
normal cells. In addition, cyclic GMP (cGMP) and the cholin-
ergic .agonists carbamyl choline (carbachol) and cal'bamyl {3-
methylcholine (bethanechol) , which al'e capable of raising cel-
lular levels of cGMP [29], normalized the surface distribution 
of Con A on CH PMN leukocytes and antagonized the colchi-
cine effect on normal PMN leukocytes. We extended these 
studies to man [30] and showed that an extreme degree of 
spontaneous Con A cap formation is also characteristic of 
peripheral blood PMN leukocytes from CH patients. Again, 
cGMP, carbachol, and bethanechol reduced spontaneous cap-
ping. 
When normal peripheral blood monocytes are incubated on 
surfaces in medium supplemented with serum, they mature in 
5 to 10 days into typical macrophages, with long cell processes, 
and a large complement of lysosomal granules [31]. When 
placed in tissue culture monocytes isolated from the blood of 
patients with the CH syndl'ome generate large, irregular gran-
ules. When the same cells matUl'e in the presence of cal'bachol 
or bethanechol, the proportion of cells containing morphologi-
cally normal granules is increased significantly [30]. The addi-
tion to human PMN leukocytes of cGMP or agents that en-
hance cellular concentrations of the nucleotide promotes micro-
tubule assembly in these cells [32]. Thus, CH PMN leukocyte 
membranes behave like membranes of colchicine-treated nor-
mal cells in which microtubules are depolymerized; this obser-
vation suggests that microtubule function is impaired in the CH 
syndrome, perhaps secondal'Y to an abnormality in cGMP 
generation. Electron microscopic studies [33] confirmed the fact 
that the characteristic extensive assembly of microtubules ob-
served in normal human PMN leukocytes incubated with Con 
A [34] does not occur in PMN leukocytes from patients with 
the CH syndrome. However, incubation of human CH PMN 
leukocytes with cGMP or cholinergic agonists resulted in a 
marked increase in the numbers of centriole-associated micro-
tubules when these cells were exposed to Con A [33]. The 
electron microscopic findings suggest that in CH PMN leuko-
cytes the defect is in the assembly of microtubules rather than 
in the function of alTeady intact ones. 
Microtubules are in a dynamic state of assembly and disas-
sembly, but it is probably in their aggregated state that they 
exert their influence on cell mechanics [35]. Tubulin, a dimeric 
protein with a molecular weight of approximately 115,000, has 
been identified as the major constituent from which microtu-
buies are assembled [36]. Neither synthesis by the CH cell of 
altered tubulin nor a reduction in the amount of tubulin avail-
able appears to explain the inadequate microtubule assembly 
that we observed in CH mice: CH mouse brain tubulin copo-
lymerizes with rabbit brain tubulin no less than tubulin from 
normal black mouse brain [37]. In addition, the amounts of 
tubulin in CH mouse liver, splenic lymphocytes, and granulo-
cytes were comparable to those found in the same tissues in 
control animals. * Further evidence for a microtubule defect in 
human CH cells was obtained from studies [38] in which 
vinblastine induced paracrystal formation (visible by phase 
contrast microscopy) in only 20% of cells from 4 CH fibroblast 
• Sherline P, Zurier RB, unpublished data. 
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lines but in 80% of normal human fibroblasts Moreover a 
reduced association of antitubulin antibody with cytoplas~ic 
filamentous structures (by immunofluorescence), presumed to 
be microtubules, in confluent mouse CH fibroblasts compared 
to fibroblasts from normal mice has been observed [33]. CH 
fibroblasts incubated overnight with 10- 5 M cru'bachol showed 
enhancement of filamentous staining with antitubulin. 
Biochemical confil'mation of impail'ed cGMP generation by 
CH cells has not been forthcoming. However, Boxer et al [39] 
have shown that the cyclic AMP (cAMP) levels in PMN 
leukocytes from patients with the CH syndl'ome ru'e 8 times 
higher than those found in normal PMN leukocytes, and that 
ascorbic acid (10 mM) added in vitro substantially reduces 
cAMP levels in leukocytes from CH patients. Boxer et al [40] 
showed that incubation of CH PMN leukocytes with bethane-
chol or treatment of CH patients with this cholinergic agonist 
corrects defects in PMN chemotaxis and bactericidal activity. 
Because ascorbic acid increases cGMP levels in human periph-
eral blood monocytes [41], Boxer and his colleagues adminis-
tered vitamin C (200 mg/ day) to an infant with the CH syn-
dl·ome. Treatment corrected the PMN functional defects 
(chemotaxis, bactericidal activity), reduced cellular cAMP to 
nearly normal levels, and prevented the recurrent infections 
that had plagued the patient [39]. All responses were reversed 
after withdl'awal of ascorbate. Ascorbic acid treatment has 
provided symptomatic relief for several other CH patients in 
North America and EUl'ope. t It is not yet c1eru' whether vitamin 
C can prevent or alleviate the accelerated, lymphoma-like phase 
of the CH syndl'ome. 
MURINE LUPUS 
In the f, hybrid of New Zealand black and white (NZB/ W) 
mice, a disease ("murine lupus") that is remal'kably similar to 
SLE in human beings [42] develops. It is chru'acterized by the 
appearance of antibodies to nucleal' constituents and the sub-
sequent development of an immune-complex-mediated glomer-
ulonephl'itis [43]. Immunofluorescence studies have shown that 
host immunoglobulin and complement accumulate in the glo-
l' Br>xer L, Biggar D, Oliver JM, personal communications. 
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meruli during the course of both murine [44] and human [45] 
varieties of SLE. The progress of the disease is variable, but in 
general immune complexes are deposited rapidly in the kidney 
during months 4 to 6 [42]. Proteinuria and renal failure then 
proceed. Deposition of immunoglobulin has been consistently 
detected at the dermal-epidermal (DE) junction from month 6 
on [46,47]. Antinuclear antibodies develop in the majority of 
mice from months 6 to 9 [48]; circulating antibodies to DNA 
also develop at that time [49]. Mice generally die between 
months 6 and 14. The immune status of NZB/W mice can be 
characterized as an imbalance in which B cell activity and 
humoral antibody responses are excessive, and T cell activity 
and cell-mediated immunity are suppressed [48]. 
Because there was evidence [50-52] that prostaglandin EI 
(PGE 1) could enhance T cell and suppress B cell activity, we 
treated NZB/W mice with PGE 1• Continuous treatment of 
female NZB/W mice with pharmacological doses (200 /lg once 
or twice daily) of PGE 1 for 1 year did in fact prevent clinical 
nephritis and death in these animals despite the fact that 
treatment did not prevent development of antibodies to nuclear 
antigens [53]. Thus 17 of 19 treated mice were still alive dming 
week 58 (Figure). In addition, PGE 1 treatment prevented glo-
merular deposition of immunoglobulins and complement, and 
development of the proliferative glomerulonephritis character-
istic of untreated NZB/W mice [54]. At the DE junction, 
deposition of IgG was detected by immunofluorescence in 7 of 
the 12 PGEI-treated female mice examined. Only 1 animal 
showed skin deposition of IgM, and none had IgA deposition. 
At the DE junction in untreated animals, IgG deposition was 
seen in 10 of 11 mice and IgM deposition was seen in 7 of 11 
mice; IgA deposition was seen in only one untreated NZB/W 
mouse. 
The mechanisms whereby PGE 1 exerts its striking effects on 
murine lupus and the events responsible for renal deposition of 
immune complexes have not been precisely defined. Complex 
size and solubility, antigen-antibody ratio, and avidity of anti-
body for antigen all are important factors [55-57]. It will be 
necessary to determine whether PGE 1 treatment influences 
these factors and/or the class of antibodies to nuclear materials 
that do develop. The age-related loss of responsiveness ('IH_ 
thymidine incorporation studies) to phytohemagglutinin ex-
hibited by spleen cells from NZB/ W mice [58] is significantly 
less in cells from NZB/ W mice treated with PGE 1 [59]. It is not 
clear, however, whether PGE 1 in vivo actually enhances cell-
mediated immunity or whether preservation of the in vitro 
response is secondary to good health induced by PGE 1 in some 
other manner. In many in vitro systems the effects of PGE 1 are 
due to its capacity to increase cellular levels of cAMP [2]. 
PGF2n has a minimal influence on cellular levels of this nucleo-
tide. The failme of PGF2n treatment to alter the course of 
murine lupus [60] suggests that the protection afforded NZB/W 
mice by PGE 1 treatment may be mediated by cAMP. Whatever 
the mechanisms be whereby PGE 1 protects NZB/ W mice from 
nephritis and death, their investigation should lead to a better 
understanding of human SLE. 
Prostaglandins were generously provided by Dr. John Pike, the 
Upjohn Company, Kalamazoo, Michigan. The manuscrip t was typed 
by Ms. Barbara Peterson. 
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tology, University of California School of Medicine, San Francisco, will be held on August 26-27 in San 
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